Pituitary tumors

Current Opinion in Neurology

Volumn 25, Issue 6, 2012, Pages 751-755

  Mehta, Gautam U ^a   Jane, John A ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

pituitary tumors; radiosurgery; surgery; treatment

Indexed keywords

ANGIOPEPTIN; BROMOCRIPTINE; OCTREOTIDE; TEMOZOLOMIDE;

ACROMEGALY; CANCER RADIOTHERAPY; CLINICAL PRACTICE; HUMAN; HYPOPHYSIS ADENOMA; HYPOPHYSIS TUMOR; LIQUORRHEA; LONG TERM CARE; MICROSURGERY; MORBIDITY; PATIENT CARE; PERSONALIZED MEDICINE; PROLACTINOMA; REVIEW; STEREOTACTIC RADIOSURGERY; TRANSSPHENOIDAL SURGERY; TUMOR LOCALIZATION; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT;

ACROMEGALY; ADENOMA; ANTINEOPLASTIC AGENTS; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HUMANS; HYPERPROLACTINEMIA; NEUROSURGICAL PROCEDURES; PITUITARY NEOPLASMS; PROLACTINOMA; RADIOSURGERY; RADIOTHERAPY;

EID: 84870059562     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0b013e3283587bed     Document Type: Review

References (38)

1. Molitch ME. Nonfunctioning pituitary tumors and pituitary incidentalomas. Endocrinol Metab Clin North Am 2008; 37:151-171.
2. Melmed S, Colao A, Barkan A, et al. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 2009; 94:1509-1517.
3. Melmed S. Update in pituitary disease. J Clin Endocrinol Metab 2008; 93:331-338. (Pubitemid 351240799)
4. Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96:273-288.
5. Freda PU, Beckers AM, Katznelson L, et al. Pituitary incidentaloma: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96:894-904.
6. dos Santos Nunes V, Dib El R, Boguszewski CL, Nogueira CR. Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis. Pituitary 2011; 14:259-265.
7. Schlechte J, Dolan K, Sherman B, et al. The natural history of untreated hyperprolactinemia: a prospective analysis. J Clin Endocrinol Metab 1989; 68:412-418. (Pubitemid 19052886)
8. Fadul CE, Kominsky AL, Meyer LP, et al. Long-term response of pituitary carcinoma to temozolomide. Report of two cases. J Neurosurg 2006; 105:621-626. (Pubitemid 44525896)
9. Sheehan J, Rainey J, Nguyen J, et al. Temozolomide-induced inhibition of pituitary adenoma cells. J Neurosurg 2011; 114:354-358.
10. Dillard TH, Gultekin SH, Delashaw JB, et al. Temozolomide for corticotroph pituitary adenomas refractory to standard therapy. Pituitary 2011; 14:80-91.
11. Morin E, Berthelet F, Weisnagel J, et al. Failure of temozolomide and conventional doses of pegvisomant to attain biochemical control in a severe case of acromegaly. Pituitary 2012; 15:97-100.
12. Maiza JC, Vezzosi D, Matta M, et al. Long-term (up to 18 years) effects on GH/ IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa. Clin Endocrinol (Oxf) 2007; 67:282-289. (Pubitemid 47076308)
13. Grozinsky-Glasberg S, Shimon I, Korbonits M, Grossman AB. Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms. Endocr Relat Cancer 2008; 15:701-720.
14. Chahal HS, Stals K, UnterländerM, et al. AIP mutation in pituitary adenomas in the 18th century and today. N Engl J Med 2011; 364:43-50.
15. Vierimaa O, Georgitsi M, Lehtonen R, et al. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science 2006; 312:1228-1230. (Pubitemid 43801151)
16. Chahal HS, Trivellin G, Leontiou CA, et al. Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway. J Clin Endocrinol Metab 2012; 97:E1411-E1420.
17. van der Lely AJ, Biller BMK, Brue T, et al. Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. J Clin Endocrinol Metab 2012; 97:1589-1597.
18. Filopanti M, Olgiati L, Mantovani G, et al. Growth hormone receptor variants and response to pegvisomant in monotherapy or in combination with somatostatin analogs in acromegalic patients: a multicenter study. J Clin Endocrinol Metab 2012; 97:E165-E172.
19. Vilar L, Azevedo MF, Naves LA, et al. Role of the addition of cabergoline to the management of acromegalic patients resistant to longterm treatment with octreotide LAR. Pituitary 2011; 14:148-156.
20. Bernabeu I, Alvarez-EscoláC, Paniagua AE, et al. Pegvisomant and cabergoline combination therapy in acromegaly. Pituitary 2012. doi:10.1007/s11102-012-0382-z. [Epub ahead of print]
21. Sandret L, Maison P, Chanson P. Place of cabergoline in acromegaly: a metaanalysis. J Clin Endocrinol Metab 2011; 96:1327-1335.
22. Kanter AS, Dumont AS, Asthagiri AR, et al. The transsphenoidal approach. A historical perspective. Neurosurg Focus 2005; 18:e6.
23. Hardy JJ. Transphenoidal microsurgery of the normal and pathological pituitary. Clin Neurosurg 1969; 16:185-217.
24. Jankowski R, Auque J, Simon C, et al. Endoscopic pituitary tumor surgery. The Laryngoscope 1992; 102:198-202.
25. Locatelli M, Bertani G, Carrabba G, et al. The trans-sphenoidal resection of pituitary adenomas in elderly patients and surgical risk. Pituitary 2012.doi:10.1007/s11102-012-0390-z. [Epub ahead of print]
26. Babey M, Sahli R, Vajtai I, et al. Pituitary surgery for small prolactinomas as an alternative to treatment with dopamine agonists. Pituitary 2011; 14:222-230.
27. Komotar RJ, Starke RM, Raper DMS, et al. Endoscopic endonasal compared with microscopic transsphenoidal and open transcranial resection of giant pituitary adenomas. Pituitary 2012; 15:150-159.
28. Berkmann S, Fandino J, Zosso S, et al. Intraoperative magnetic resonance imaging and early prognosis for vision after transsphenoidal surgery for sellar lesions. J Neurosurg 2011; 115:518-527.
29. Litvack ZN, Zada G, Laws ER. Indocyanine green fluorescence endoscopy for visual differentiation of pituitary tumor from surrounding structures. J Neurosurg 2012; 116:935-941.
30. Black PM, Zervas NT, Candia GL. Incidence and management of complications of transsphenoidal operation for pituitary adenomas. Neurosurgery 1987; 20:920-924. (Pubitemid 17113129)
31. Ciric I, Ragin A, Baumgartner C, Pierce D. Complications of transsphenoidal surgery: results of a national survey, review of the literature, and personal experience. Neurosurgery 1997; 40:225-236.
32. Cho JM, Ahn JY, Chang JH, Kim SH. Prevention of cerebrospinal fluid rhinorrhea after transsphenoidal surgery by collagen fleece coated with fibrin sealant without autologous tissue graft or postoperative lumbar drainage. Neurosurgery 2011; 68:130-136.
33. Mehta GU, Oldfield EH. Prevention of intraoperative cerebrospinal fluid leaks by lumbar cerebrospinal fluid drainage during surgery for pituitary macroadenomas. J Neurosurg 2012; 116:1299-1303.
34. Loeffler JS, Shih HA. Radiation therapy in the management of pituitary adenomas. J Clin Endocrinol Metab 2011; 96:1992-2003.
35. Snead FE, Amdur RJ, Morris CG, Mendenhall WM. Long-term outcomes of radiotherapy for pituitary adenomas. Int J Radiat Oncol Biol Phys 2008; 71:994-998.
36. Sheehan JP, Pouratian N, Steiner L, et al. Gamma Knife surgery for pituitary adenomas: factors related to radiological and endocrine outcomes. J Neurosurg 2011; 114:303-309.
37. Gopalan R, Schlesinger D, Vance ML, et al. Long-term outcomes after Gamma Knife radiosurgery for patients with a nonfunctioning pituitary adenoma. Neurosurgery 2011; 69:284-293.
38. Park K-J, Kano H, Parry PV, et al. Long-term outcomes after Gamma Knife stereotactic radiosurgery for nonfunctional pituitary adenomas. Neurosurgery 2011; 69:1188-1199.